Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCIR trial of gemcitabine + cisplatin + immune checkpoint inhibitor with or without endoscopic radiofrequency ablation in unresectable biliary tract cancer
jRCT1051260084Phase 3Recruiting
- Start
- Aug 2026
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin, durvalumab and pembrolizumab in biliary cancer (2 arms). Primary endpoint: Progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
03
Conditions
biliary cancer
Beyond the preview
Go deeper on jRCT1051260084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051260084.